The ClinGen Evidence Repository is an FDA-recognized human genetic variant database containing expert-curated assertions regarding variants' pathogenicity and supporting evidence summaries. [Disclaimer]


Variant: NM_000152.5(GAA):c.2105G>C (p.Arg702Pro)

CA401370504

593593 (ClinVar)

Gene: GAA
Condition: glycogen storage disease II
Inheritance Mode: Autosomal recessive inheritance
UUID: 553c6303-639d-49e6-b287-9e2b3168adba

HGVS expressions

NM_000152.5:c.2105G>C
NM_000152.5(GAA):c.2105G>C (p.Arg702Pro)
NC_000017.11:g.80113282G>C
CM000679.2:g.80113282G>C
NC_000017.10:g.78087081G>C
CM000679.1:g.78087081G>C
NC_000017.9:g.75701676G>C
NG_009822.1:g.16727G>C
ENST00000570803.6:c.2105G>C
ENST00000572080.2:c.*243G>C
ENST00000577106.6:c.2105G>C
ENST00000302262.8:c.2105G>C
ENST00000302262.7:c.2105G>C
ENST00000390015.7:c.2105G>C
ENST00000572080.1:c.524G>C
NM_000152.3:c.2105G>C
NM_001079803.1:c.2105G>C
NM_001079804.1:c.2105G>C
NM_000152.4:c.2105G>C
NM_001079803.2:c.2105G>C
NM_001079804.2:c.2105G>C
NM_001079803.3:c.2105G>C
NM_001079804.3:c.2105G>C

Uncertain Significance

Met criteria codes 4
PP3 PM5 PM3_Supporting PM2_Supporting
Not Met criteria codes 1
PP4

Evidence Links 0

Expert Panel

Criteria Specification Information

Criteria Specification: ClinGen Lysosomal Storage Disorders Variant Curation Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines Version 2

PDF
Criteria Specification Approval History
Criteria Specifications for this VCEP
Evidence submitted by expert panel
Lysosomal Diseases VCEP
The NM_000152.5:c.12105G>C variant in GAA is a missense variant predicted to cause substitution of arginine by proline at amino acid 702 (p.Arg702Pro). It has been reported in one individual in national mutation database for the country of Oman (PMID: 26594346). However, no clinical details were provided and thus points can not be applied for PP4. This individual was compound heterozygous for the variant and variant classified as pathogenic by the ClinGen LD VCEP (c.2560C>T, p.Arg854Ter; ClinVar Variation ID: Variation ID: 4034, SCV001371731.1), phase unknown (PMID: 26594346) (PM3_supporting). This variant is absent in gnomAD v2.1.1. (PM2_Supporting). The computational predictor REVEL gives a score of 0.989 which is above the threshold of 0.7, evidence that correlates with impact to GAA function (PP3). Another missense variant [c.2105G>T, p.Arg702Leu] in the same codon has been classified as pathogenic for Pompe disease by the ClinGen Lysosomal Diseases VCEP (ClinVar Variation ID: Variation ID: 92472) (PM5). There is a ClinVar entry for this variant (Variation ID: 593593). Due to insufficient evidence, this variant is classified as a variant of unknown significance for Pompe disease based on the GAA-specific ACMG/AMP criteria applied, as specified by the ClinGen Lysosomal Diseases Variant Curation Expert Panel (Specifications Version 2.0): (PM5, PM3_supporting, PM2_supporting, PP3). (Classification approved by the ClinGen Lysosomal Diseases Variant Curation Expert Panel on March 5, 2024).
Met criteria codes
PP3
The computational predictor REVEL gives a score of 0.989 which is above the threshold of 0.7, evidence that correlates with impact to GAA function (PP3).
PM5
Another missense variant [c.2105G>T, p.Arg702Leu] in the same codon has been classified as pathogenic for Pompe disease by the ClinGen Lysosomal Diseases VCEP (ClinVar Variation ID: Variation ID: 92472) (PM5)
PM3_Supporting
This variant has been detected in one individual described as having Pompe disease. This individual was compound heterozygous for the variant and a known pathogenic variant (c.2560C>T), phase unknown. (PM3_supporting).
PM2_Supporting
This variant is absent in gnomAD v2.1.1. (PM2_Supporting). // The highest population minor allele frequency in gnomAD v4.0.0 is 0.0000009 (1/1105906 alleles) in the European (non-Finnish) population, which is lower than the ClinGen Lysosomal Diseases VCEP’s threshold for PM2_Supporting (<0.001), meeting this criterion (PM2_Supporting).
Not Met criteria codes
PP4
There is one reported individual in the literature enrolled in a national mutation database in Oman (PMID: 26594346) described as having Glycogen Storage Disease II. There are no additional clinical details thus we cannot apply PP4.
Approved on: 2024-03-05
Published on: 2024-03-26
The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.
¤ Powered by BCM's Genboree.